Changes in the board structure of Latvian Medicines Verification Organisation

A new board member Evita Jaunzeme, who is representing manufacturers of innovative medicinal products (Association of International Innovative Pharmaceuticals Producers) and manufacturers of generic medicinal products (Latvian Generic Medicines Association), has been appointed on the board of Latvian Medicines Verification Organisation (LZVO) since December 8, 2020. E. Jaunzeme is Gedeon Richter Plc. Head of the Representation in Latvia.

E. Jaunzeme is a high-class professional with more than 20 years of experience in a leading position in the pharmaceutical industry in Latvia. E. Jaunzeme also actively participates in the work of professional organizations.

The Executive Director of LZVO Inese Erdmane continues her work on the board, as well as Mārcis Rutulis, who is representing the distributors of parallel imported medicinal products (Latvian Parallel Medicines Import Association), medicinal product wholesalers (Latvian Association of Pharmaceutical Wholesalers), and pharmacies (Association of Pharmacy Owners). E. Jaunzeme will replace Daina Dzirkale, the External Affairs Director of SIA GlaxoSmithKline Latvia, who left the Board due to a change of job.

“The Latvian Medicines Verification Organisation thanks Daina Dzirkale for her work on the Board so far – Daina's analytical mind, broad vision and detailed knowledge helped LZVO to develop and strengthen it as an effective, stable and reliable medicines safety testing system. We will continue to keep the bar of LZVO's operational quality equally high in the new composition of the Board,” says Inese Erdmane, Chairperson of the Board of LZVO.

LZVO maintains and manages the Latvian system of medicine verification or safety control, which, since 9 February 2019 has been in operation in more than 30 European countries. The development of medicines verification system is provided for by the EU Falsified Medicines Directive (2011/62/EU) and the Commission Delegated Regulation (EU 2016/161) that lays down detailed rules for the safety features appearing on the packaging of medicinal products for human use.